HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

SMN-targeted therapeutics for spinal muscular atrophy: are we SMArt enough yet?

Abstract
Spinal muscular atrophy (SMA) remains one of the most common and lethal autosomal recessive diseases. Homozygous deletion of survival of motor neuron 1 (SMN1) and resulting SMN protein deficiency manifests predominantly with motor neuron degeneration; however, a wealth of emerging data supports a broader influence of SMN deficiency in disease pathogenesis. In this issue of the JCI, Kariya and colleagues demonstrate the relatively selective impact of SMN depletion on the distal motor unit using a series of SMN2-expressing transgenic mice in which constitutive SMN knockdown follows variable periods of normal development. Their observations provide further insights regarding the temporal requirements for SMN in mice, renewing speculation about when and where repletion of SMN is necessary for optimal outcomes in SMA patients.
AuthorsKathryn J Swoboda
JournalThe Journal of clinical investigation (J Clin Invest) Vol. 124 Issue 2 Pg. 487-90 (Feb 2014) ISSN: 1558-8238 [Electronic] United States
PMID24463455 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Comment)
Chemical References
  • Smn1 protein, mouse
  • Survival of Motor Neuron 1 Protein
Topics
  • Animals
  • Female
  • Male
  • Neuromuscular Junction (metabolism)
  • Survival of Motor Neuron 1 Protein (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: